Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysisMakoto Tahara, Douglas Adkins, Assuntina G. Sacco et al.|Annals of Oncology|2019Cited by 0